Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most common subtype of non-Hodgkin lymphoma (NHL), accounting for about 30% of B-cell NHL, with an estimated 8,500 new cases each ...
Read moreThis is a phase 1 clinical trial part of the European H2020 ICOD project (Improving COgnition in Down syndrome) coordinated by Prof. Raphael de la Torre Fornell.
Read moreUn año más, el Vall d’Hebron Instituto de Oncología (VHIO) y el Hospital Universitario Vall d’Hebron (HUVH) han programado un ciclo de jornadas online para 2022 en las que se abordarán diferen...
Read moreUn sistema para la fotodesinfección nasal podría eliminar el reservorio del virus en la nariz del paciente contagiado, evitando así que infecte a otras personas.
Read morePORTICO (EudraCT No.: 2020-003469-20, ClinicalTrials.gov Identifier NCT04932291) is a multicenter, double-blind, randomized, placebo-controlled, Phase IIb trial to evaluate the efficacy and safety of ...
Read moreDos ensayos clínicos internacionales liderados por la Clínica Universidad de Navarra ofrecen una alternativa terapéutica –el fármaco nivolumab- para los pacientes con cáncer de hígado que no s...
Read moreNorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, announces it has initiated a Phase 1 stud...
Read moreAn international study led by I3PT notes that clinical trials may account for only about one-fifth of people in the real world with schizophrenia spectrum disorders, and points out that new studies sh...
Read moreInvestigadores del IBiS, liderados por el Dr. Jesús Rodríguez Baño del IBiS/CSIC/US, facultativos de Enfermedades Infecciosas y Microbiología en el Hospital Universitario Virgen Macarena y CIBERIN...
Read moreA study led by researchers from the Hospital Clínic-IDIBAPS shows that a new treatment without chemotherapy is effective in treating indolent clinical forms of mantle cell lymphoma. With this therapy...
Read moreThe Vall d’Hebron Institute of Oncology (VHIO) has enrolled the first patient in the NoCanTher project’s clinical trial, representing an important step in bringing in nano-driven therapeutics as n...
Read more